Parkinson's Disease (PD) affects approximately 3 in 1000 Canadians. 1 The incidence in age matched cohorts has increased over the years and our aging population will mean even more cases in the future. 2 Despite the best available medical therapy, there continues to be a large segment of the parkinsonian population that continues to have significant disability and for whom alternate treatment strategies are important.
Pathophysiological rationale for pallidotomy
In PD, loss of dopaminergic input to the striatum leads to overactivity of the basal ganglia output structures, the internal segment of the globus pallidus (GPi ) and the substantia nigra pars reticulata (SNR). 14, 15 Current models of basal ganglia function suggest that the heightened GABAergic inhibitory outflow from these output nuclei in parkinsonian states "overinhibits" both thalamic targets (and hence downstream cortical fields) and brainstem targets, leading to the disturbances of motor function. 16, 17 The rationale for surgery is based on disrupting this abnormal activity in GPi through lesioning (or chronic electrical blockade) to disinhibit the motor thalamus and cortical motor areas and to normalize motor function. Indeed activation of the supplementary motor area (SMA) has been demonstrated with functional brain imaging following pallidotomy 18, 19 (and pallidal deep brain stimulation). 20 However, the contribution of descending pallidal-brainstem pathways, which are poorly defined, is not yet understood. Disinhibition of these pathways (e.g., pedunculopontine, tectospinal) may underlie some the effects of pallidotomy, particularly the axial manifestations of PD and postural instability and gait disturbance (PIGD).
Indications for pallidotomy
Ideal candidates for surgery are patients with the diagnosis of idiopathic PD who (1) continue to be disabled despite the best available medical treatment, (2) have a history of responsiveness to L-dopa, and (3) have developed complications of long-term L-DOPA treatment (motor fluctuations, wearing-off, drug-induced involuntary movements(dyskinesia)). A complete course of pharmacotherapy is mandatory before surgery, but it is important to recognize when diminishing gains can be expected from medication changes. Contraindications to surgery include (1) parkinsonian syndromes other than PD, (2) fragile medical condition, and (3) cognitive impairment. Parkinsonian features that respond to pallidotomy include drug induced dyskinesias, rigidity, tremor, and bradykinesia. Speech, cognitive, psychiatric, autonomic and gait disturbances are less responsive or unresponsive to unilateral pallidotomy.
Outcome of pallidotomy
Leksell provided evidence that targeting the posteroventral (PV) pallidum was more effective than the previous target in the anterodorsal pallidum. 21 Laitinen et al. confirmed the efficacy of PV pallidotomy in 38 patients. 4 Two early pilot series used the Core Assessment Program for Intracerebral Transplantation (CAPIT) protocol, 22 which incorporates the United Parkinson's Disease Rating Scale (UPDRS), a dyskinesia rating scale and timed motor tests, to demonstrate the efficacy of microelectrodeguided GPi pallidotomy.
5, 23 A number of studies have now shown efficacy at three and six months, with improvements in off-period UPDRS total motor scores (17 -46% decrease from baseline) and on-period drug-induced dyskinesias (43 -92% decrease). [5] [6] [7] [8] [9] [10] [11] [12] [13] 23 Improvements in on-period functioning have generally not been reported, except for dyskinesia, although patients spend more time in the on-period. Effects are greater for contralateral bradykinesia, rigidity and tremor than for ipsilateral signs. Improvements in PIGD are less significant (31% decrease) and more short-lived. 11, 12 Longer-term trials have demonstrated continued efficacy for off-period signs (except PIGD) at two years 12 and three years 13 follow-up. The benefits gained from pallidotomy are associated with improvements in patients' activities of daily living, and can restore some measure of functional independence in patients. 12 The proximity of the posteroventral pallidum to the optic tract and internal capsule subjects these structures to risk from pallidotomy. Transient effects consist mainly of facial paresis or dysarthria related to encroachment of edema along the internal capsule. Transient changes in mental status are not uncommon. The incidence of visual field defects ranges from 0 -8% in series that used microelectrode mapping for target selection, 12, 24 and 0 to 40 % in those series that did not. 21, 25 THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES Suppl. 2 -S46 
Vim thalamus DBS for tremor
The ventral lateral thalamic nuclei are populated by neurons that fire in synchronous bursts whose timing is similar to peripheral tremor as originally described by Guiot et al., in 1962. 26 Neurosurgeons have known that intraoperative electrical stimulation in areas of the thalamus populated by tremor-synchronous cells can be sufficient to momentarily arrest tremor. Lesions in the ventral intermediate nucleus (Vim thalamotomy) are highly effective but can be associated with motor, sensory, cerebellar, speech and other complications. Because of the potential serious complications and the irreversible nature of lesioning the nervous system, neurosurgeons have sought alternate procedures to achieve the effectiveness of thalamotomy while reducing the risk of unwanted effects.
The work of Benabid and his colleagues 27 in 117 patients (80 PD, 20 essential tremor and 17 other) indicates that chronic VIM stimulation is highly effective for tremor, with over 85% of patients having a very good or excellent response with little or no tremor evident in the contralateral arm. While effective for tremor, VIM stimulation did not influence bradykinesia or rigidity. Recently, Koller et al. 28 have shown an 80% reduction in contralateral arm tremor in 29 patients with essential tremor (ET) and 24 patients with PD tremor with VIM DBS at one year follow up. This was associated with a greater improvement in disability for ET patients than for PD patients who have associated non-tremor motor dysfunction. The side effects of stimulation are reversible, and usually mild and accepted provided the intensity of stimulation produces significant benefits on tremor.
Globus pallidus DBS
To date, several reports outlining the clinical features of bilateral GPi stimulation have appeared. Siegfried and his group 29 used a monopolar electrode with stimulation parameters of 130 HZ, 210 microseconds, and intensities of 0.75 to 1 volt. They reported improvements in all parkinsonian symptoms with bilateral GPi stimulation. Benefits were observed in bradykinesia, gait, speech and drug induced dyskinesias. Other groups 30, 31 have also reported striking improvements in all major parkinsonian features with GPi stimulation, while another 32 has found it to be of lesser benefit. The clinical effects are dependent on which parts of the pallidum are stimulated and which stimulating parameters are used. 33, 34 Recent functional imaging data 20 suggest that GPi stimulation improves parkinsonian features by activating supplementary motor cortical areas whose underactivity in PD is thought to underlie major clinical signs and symptoms. This finding suggests that pallidal stimulation blocks GPi overactivity to disinhibit the downstream thalamus and thalamocortical system. These preliminary results support the therapeutic effectiveness of GPi stimulation and indicate that this therapeutic modality warrants further study. Recent work shows that pallidotomy can be combined with contralateral pallidal DBS to provide clinical benefit with the advantage of the reversibility of DBS.
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STN stimulation
Subthalamic nucleus (STN) stimulation represents an exciting new development in Parkinson's disease surgery. STN is glutamatergic and drives both GPi and the SNr, the two nuclei which constitute the collective output of the basal ganglia. It is therefore strategically situated to exert a powerful influence on motor function. Reducing STN activity would diminish the driving of LE JOURNAL CANADIEN DES SCIENCES NEUROLOGIQUES Suppl. 2 -S47 GPi and SNr thereby lessening the inhibition of thalamocortical projections and the motor cortical system. Such an intervention would thus be expected to facilitate movement.
Because the prospects of hemiballism are unacceptable, lesioning STN has so far not been routinely used in humans. In a pioneering report from Benabid and his colleagues, 36 three patients undergoing bilateral STN stimulation with implanted quadripolar electrodes showed striking improvements in all motor disabilities in Parkinson's disease. In these patients evaluated using the UPDRS scale three months after surgery, activity of daily living scores improved by 58-88%, and motor scores by 42-84%. This has been recently confirmed in a larger series. 37 Our own results 38 in seven patients evaluated in double-blind fashion six months after bilateral STN DBS electrode insertion are shown in the figure below show a similar level of benefit. Stimulation parameters and drugs were adjusted to avoid dyskinesias, particularly those induced by stimulation.
The mechanism of action of STN stimulation is not known. The simplest hypothesis is that the stimulation reduces or inactivates STN excitatory glutamatergic projections which drive the inhibitory GPi and SNr. Whatever the mechanism, STN stimulation represents an important development in the understanding and treatment of movement disorders.
TRANSPLANTATION
Medications and basal ganglia surgery can produce symptomatic improvement in PD but neither corrects the underlying pathology of the disease: dopamine deficiency due to loss of midbrain substantia nigra pars compacta neurons. 39 Transplantation therapy offers the possibility of replacing these lost neurons. [40] [41] This review will focus on the clinical application of neural transplantation for PD. Clinical trials have utilized i) adrenal medulla, [42] [43] [44] [45] [46] [47] ii) fetal mesencephalon, [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] and iii) xenografts 61 as a source of dopaminergic secretion.
Adrenal Medulla Grafts
The first clinical trial of transplantation for PD used autologous adrenal medulla. 42 Studies in rodents showed that motor behaviour caused dopaminergic depletion could be reversed by adrenal medullary grafts. 62 Adrenal chromaffin cells are known to secrete dopamine (as a precursor to adrenaline). 63, 64 Backlund et al. 42 therefore hoped to replace the reduced striatal dopamine in PD by direct implantation of dopamine secreting adrenal chromaffin cells. Autologous adrenal medullary grafts avoid the immune rejection and ethical considerations inherent in fetal mesencephalon transplants.
The first patient was treated in Lund, Sweden in 1982. An adrenalectomy was performed under general anaesthetic, the medulla was dissected out and then stereotaxically implanted into his caudate. The motor improvements were modest and short lived. 42 Two additional patients also had little benefit. 43 Soon thereafter, two Mexican patients were reported to have dramatic effects following a similar operation. 44 Although this later trial THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES
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Figure 3: Percent improvement in parkinsonian features (UPDRS motor, akinesia, rigidity, tremor and gait/posture scores) with STN stimulators turned on in 6 PD patient in the "off" drug state studied in a double blind fashion six months after bilateral STN DBS implants. (Data from R Kumar, AE Lang and AM Lozano)
was done without standard motor rating scales, it spurred a tremendous interest in adrenal medullary grafting. During the next two years, over 300 patients were transplanted in North America, with disappointing results. Modest improvements in motor scores were seen in 30% of patients but this was outweighed by the high morbidity and mortality of adrenalectomy in these patients. 65 As a result, clinical adrenal transplants have been abandoned in Canada, Europe and the United States. Basic research continues on co-transplanting growth factors to enhance adrenal tissue survival and function. 66
Fetal Mesencephalon Grafts
A combination of factors led to human fetal mesencephalon clinical trials. First, fetal mesencephalon grafts produced better motor improvement than adrenal medullary grafts in rodent and primate models of PD. 64 Second, transplanting neurons offered the potential for synaptic communication and thus modulation between the graft and the host (chromaffin cells could act only as cellular mini-pump). 67 Third, the clinical trials using chromaffin cells were unsuccessful. 65 Early studies of fetal mesencephalon transplants from China, Mexico and Sweden showed promising results. Following technical modifications designed to improve transplant survival, Lindvall reported reduced rigidity and off time in two patients. 51 Positron emission tomography (PET) at the University of British Columbia showed increased flurodopa uptake (a sign of graft survival and function) eight months post-transplant in these patients. Subsequent studies confirmed these promising results. [52] [53] [54] The impact of the Yale study, however, was lessened by a post mortem diagnosis of striatonigral degeneration in one of their four patients. 52 Some studies with poor outcomes were criticized for using techniques unconducive to transplant survival. 55 The most impressive data came from Lund where two patients with a parkinsonism secondary to poisoning from 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) were dramatically improved (one coming off all medications) with PET data showing survival of the graft at two years. 54 Three important concepts developed from these studies. First, a unified rating scale was needed to compare reports from different institutions. 68 Second, PET imaging was crucial to demonstrate graft survival and function in vivo (an example of the PET imaging is shown in Figure 4) . Third, more work was needed to improve fetal dopaminergic neuronal survival following transplantation. Animal studies continued to expand the knowledge of fetal dopaminergic neuronal survival by determining the ideal fetal age, 69 techniques 70 and whether immunosuppression 71 is required. The latest studies have been impressive. [36] [37] [38] [39] [40] The Tampa group has reported histologic proof of graft survival eighteen months post transplant in a patient who died following an unrelated orthopaedic procedure. 72 Over 200,000 dopaminergic neurons were counted innervating the host striatum in an organotypic pattern. Ultrastructural studies demonstrated grafthost synaptic connections. This work provides proof of concept that fetal mesencephalon grafts can survive in the host striatum and improve the motor dysfunction of PD. Two randomized prospective NIH-funded trials are underway.
Despite the successful results of fetal transplantation in PD, few workers in the field believe it will be routinely used to treat their patients. The two problems facing this therapy are i) insufficient tissue (the Tampa group uses up to eight fetuses per patient) and ii) the procedural difficulty (centres must consent for infectious disease screening, sterile abortions, rapid fetal dissection and neurosurgical implantation). The field will undoubtably proceed to more wide-spread clinical use once an alternative source LE JOURNAL CANADIEN DES SCIENCES NEUROLOGIQUES Suppl. 2 -S49 of human fetal tissue is found. Basic scientists are testing i) genetically engineered cells, 73, 74 ii) encapsulated cells, 75, 76 iii) gene therapy, [77] [78] [79] [80] and iv) xenografts. 81.82 Genetically modified cells (fibroblasts with the genes for dopamine production) have reversed motor behaviours in animal models of PD but have been hindered by long-term downregulation of the genes. Encapsulated cells (dopamine secreting tumours or cell lines wrapped in polymers with size selective pores, which permit the diffusion of small molecules but exclude host antibodies or T-cells) can bypass the immune system but will not allow synaptic communication and may not provide long-term survival. The direct inoculation of genes into the striatum may allow recruitment of non-dopaminergic neurons to produce dopamine. Finally, xenografts (tissue from different species) have shown promising results in animal models. One clinical trial using fetal pig mesencephalon has completed transplants in twelve PD patients and is awaiting follow-up data.
GROWTH FACTOR THERAPY
Neurotrophic factors are secreted by target tissues and guide the development, guidance and maintenance of the neurons which innervate them. 83 The use of a dopaminergic neurotrophic factor could have three beneficial effects in PD. First, it may reduce the loss of dopaminergic neurons and thus slow the progression of the disease. Second, it may stimulate sprouting of terminals which could store more dopamine, better buffering the striatal dopamine level, and thus reduce "on-off" phenomena. Third, it may stimulate the remaining dopaminergic neurons to increase their dopamine production potentially making up for their reduced number.
Glial cell line-derived neurotrophic factor (GDNF) has been shown to increase dopaminergic neuronal survival and dopamine uptake in vitro. 84 Studies in vivo have demonstrated that GDNF can i) increase tyrosine hydroxylase expression and neurite density in the substantia nigra of rodents, 85 ii) prevent neuronal loss after nigral toxin injection in rodents, 86 and iii) improve motor function in primates made Parkinsonian by exposure to MPTP. 87 These preclinical studies have led to on going randomized, double-blind, placebo-controlled trial of GDNF intraventricular infusion in PD.
CONCLUSION
We have seen surgical treatments playing an important role in the treatment of PD in the 1950's and 1960's only to virtually disappear with the advent L-Dopa in the late 1960s. Scientific advances are now driving the renaissance in surgical therapies in the treatment of patients who continue to be disabled despite the best available medical therapies. Some of the procedures currently in use such as pallidotomy are being rediscovered while others like transplantation and stimulation are novel and exciting developments. There are many new avenues to follow, each of which will increase our understanding and the effectiveness with which PD can be treated.
